Physician profile
David S Boyer
NPI 1851381180
$1,878.31
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $224 · 2021: $604 · 2022: $68.38 · 2023: $24.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $313.47 | 2019-2021 | |
| Pfizer INC. | $264.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $177.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.58 | 2019 | |
| Novo Nordisk INC | $124.51 | 2019-2022 | |
| Biogen, INC. | $107.48 | 2019 | |
| Amgen INC. | $92.21 | 2019-2021 | |
| Abbvie INC. | $84.30 | 2019-2021 | |
| Lilly USA, LLC | $51.50 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $48.01 | 2020-2021 | |
| Boehringer Ingelheim International Gmbh | $45.00 | 2022 | |
| Radius Health, INC. | $41.73 | 2020-2021 | |
| Dynavax Technologies Corporation | $33.60 | 2021 | |
| Gilead Sciences, INC. | $30.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.01 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $24.24 | 2023 | Inspire |
| Genentech USA, INC. | $23.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.71 | 2021 | |
| Antares Pharma, INC. | $17.55 | 2019 | |
| Sanofi Pasteur INC. | $16.76 | 2019 | |
| Hologic Sales and Service, LLC | $16.19 | 2019 | |
| Amarin Pharma, INC. | $15.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.15 | 2019 | |
| Eisai INC. | $14.85 | 2021 | |
| Glaxosmithkline, LLC. | $14.36 | 2021 | |
| Janssen Scientific Affairs, LLC | $14.35 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.28 | 2019 | |
| Phadia US INC. | $14.23 | 2019 | |
| Clarus Therapeutics INC. | $14.06 | 2021 | |
| Covidien LP | $13.87 | 2019 | |
| Vistapharm, INC. | $13.64 | 2021 | |
| Allergan, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.